BioLife Solutions Inc Asset Resilience Ratio
BioLife Solutions Inc asset resilience ratio. BioLife Solutions Inc (BLFS) has an Asset Resilience Ratio of 13.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BioLife Solutions Inc (BLFS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioLife Solutions Inc (1993–2025)
Asset resilience ratio of BioLife Solutions Inc from 1993 to 2025. This chart shows how BioLife Solutions Inc's Asset Resilience Ratio has changed over time. See BioLife Solutions Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down BioLife Solutions Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BioLife Solutions Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.42 Million | 13.05% |
| Total Liquid Assets | $58.42 Million | 13.05% |
Asset Resilience Insights
- Moderate Liquidity: BioLife Solutions Inc has 13.05% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
BioLife Solutions Inc Industry Peers by Asset Resilience Ratio
Compare BioLife Solutions Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0 |
Medical Instruments & Supplies | 0.37% |
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Mingyue Optical Lens Co.Ltd.
SHE:301101 |
Medical Instruments & Supplies | 47.21% |
|
Medeon Biodesign
TWO:6499 |
Medical Instruments & Supplies | 32.68% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Nextgen
TA:NXGN |
Medical Instruments & Supplies | 3.13% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
BioLife Solutions Inc Asset Resilience Ratio by Year (1993–2025)
BioLife Solutions Inc asset resilience ratio by year from 1993 to 2025. The table below shows the annual Asset Resilience Ratio data for BioLife Solutions Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.77% | $55.89 Million | $405.88 Million | +11.47pp |
| 2024-12-31 | 2.30% | $9.20 Million | $399.49 Million | -1.64pp |
| 2023-12-31 | 3.95% | $16.29 Million | $412.71 Million | -5.66pp |
| 2022-12-31 | 9.61% | $43.26 Million | $450.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $554.29 Million | -- |
| 2020-12-31 | 2.50% | $5.87 Million | $234.83 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $12.14 Million | -- |
| 2016-12-31 | 20.83% | $1.65 Million | $7.93 Million | +7.48pp |
| 2015-12-31 | 13.35% | $1.65 Million | $12.37 Million | -32.69pp |
| 2014-12-31 | 46.04% | $7.40 Million | $16.07 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $3.35 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.66 Million | -- |
| 1996-12-31 | 1.82% | $110.15K | $6.04 Million | +0.63pp |
| 1995-12-31 | 1.19% | $100.31K | $8.40 Million | 0.00pp |
| 1994-12-31 | 1.19% | $100.31K | $8.40 Million | +0.09pp |
| 1993-12-31 | 1.10% | $100.31K | $9.10 Million | -- |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more